SAGES guideline for clinical application of laparoscopic bariatric surgery

SAGES Guidelines Committee
endorsed by the ASMBS

Received: 20 March 2008 / Accepted: 25 March 2008
©SAGES 2008

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGB</td>
<td>Adjustable gastric band</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BPD</td>
<td>Biliopancreatic diversion</td>
</tr>
<tr>
<td>DS</td>
<td>Duodenal switch</td>
</tr>
<tr>
<td>EBWL</td>
<td>Excess body weight loss</td>
</tr>
<tr>
<td>RGB</td>
<td>Roux-en-Y gastric bypass</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>VBG</td>
<td>Vertical banded gastroplasty</td>
</tr>
</tbody>
</table>

Preamble

Approximately one-third of US adults are obese [1]. The health consequences of severe obesity have been well described [2]. Current evidence suggests surgical therapies offer the best hope for substantial and sustainable weight loss in the extremely obese [3], with resultant mortality reduction [4]. These truths, coupled with improved minimally invasive bariatric procedures, have driven a fourfold increase in the population-based rate of bariatric surgery over recent years [5].

This document is intended to guide surgeons applying laparoscopic techniques to the practice of bariatric surgery. It will not address credentialing of surgeons or centers, which is the focus of SAGES Guideline for Institutions Granting Bariatric Privileges Utilizing Laparoscopic Techniques and ASMBS Guideline for Granting Privileges in Bariatric Surgery. The current recommendations are graded and linked to the evidence utilizing the definitions in appendices A and B.

This statement was prepared by the Guidelines Committee of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), with input from the Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery (ASMBS). The final document was approved by the SAGES Board of Governors June, 2008, and co-endorsed by the ASMBS Board of Governors June, 2008.

SAGES Guidelines Committee Society of American Gastrointestinal Endoscopic Surgeons (SAGES),
11300 West Olympic Boulevard, Suite 600, Los Angeles, CA 90064, USA
e-mail: sagesweb@sages.org

SAGES Disclaimer

Clinical practice guidelines are intended to indicate the best available approach to medical conditions as established by systematic review of available data and expert opinion. Recommendations are not intended to be exclusive given the complexity of the health care environment. These guidelines are intended to be flexible and should be applied with consideration of the unique needs of individual patients and the evolving medical literature. These guidelines are applicable to all physicians who are credentialed appropriately and who address the clinical situation in question, regardless of specialty. Guidelines are developed under the auspices of SAGES and the Guidelines Committee, and are approved by the Board of Governors. Each guideline undergoes multidisciplinary review and is considered valid at the time of production based on data available. Recent developments in medical research and practice pertinent to each guideline will be reviewed, and guidelines will be updated on a periodic basis.

ASMBS Disclaimer

Guidelines are not intended to provide inflexible rules or requirements of practice and are not intended, nor should they be used, to state or establish a local, regional, or national legal standard of care. Ultimately, there are various appropriate treatment modalities for each patient, and the surgeon must use judgment in selecting from among feasible treatment options.

ASMBS cautions against the use of guidelines in litigation in which the clinical decisions of a physician are called into question. The ultimate judgment regarding appropriateness of any specific procedure or course of action must be made by the physician in light of all the circumstances presented. Thus, an approach that differs from this guideline, standing alone, does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious physician may responsibly
adopt a course of action different from that set forth in the guideline when, in the reasonable judgment of the physician, such course of action is indicated by the condition of the patient, limitations on available resources or advances in knowledge or technology. All that should be expected is that the physician will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient, in order to deliver effective and safe medical care. The sole purpose of this guideline is to assist practitioners in achieving this objective.

Introduction and rationale for surgery
The United States of America has experienced a steady rise in obesity prevalence over the last 20 years and currently ranks second in the world [6]. At the turn of the millennium, nearly two-thirds of Americans were overweight or obese, and almost 5% were morbidly obese [7]. This trend is ominous, because morbid obesity predisposes patients to comorbid diseases which affect nearly every organ system. These include: type 2 diabetes, cardiovascular disease, hypertension, hyperlipidemia, hyperventilation syndrome, asthma, sleep apnea, stroke, pseudotumor cerebri, arthritis, several types of cancers, urinary incontinence, gallbladder disease, and depression [8–10]. Obesity shortens life expectancy [11], with increasing body mass index (BMI) resulting in proportionally shorter lifespan [12]. With over 300,000 victims in the USA each year, morbid obesity is projected to overtake smoking as the leading cause of death in the near future [13].

There are now more than nine million morbidly obese Americans who need help. However, nonoperative management with diet, exercise, behavior modification, and medications rarely achieves adequate durable weight loss [14]. Four long-term studies of nonoperative management of obesity showed an average weight loss of only 4% [15–18]. In the recent Swedish Obese Subjects prospective controlled study, medical management over ten years was associated with 1.6% increase in body weight compared with 13.2% weight loss after gastric band and 25% weight loss after gastric bypass [19].

Since the advent of minimally invasive therapies, there has been a dramatic increase in gastrointestinal procedures that produce significant sustainable weight loss with low complication rates [19–22]. Surgically induced weight loss is associated with resolution or improvement of comorbid diseases in 75–100% of patients [22], and reduced mortality compared with medically treated patients [23–25]. Public awareness and demand, along with improved systems for surgeon training and delivery of care, have combined to fuel a national explosion in bariatric procedures. In 2003, 102,798 operations were performed in the USA, compared with only 13,365 in 1998 [26].

Justification for surgical treatment of obesity
- Weight-loss surgery is the most effective treatment for morbid obesity, producing durable weight loss, improvement or remission of comorbid conditions, and longer life (level I, grade A).

Evolution of contemporary surgical options
Operations to alter the gastrointestinal tract and produce weight loss have been applied for half a century. Weight-loss operations may cause malabsorption, restriction of food intake, or a combination of the two. The original operation for morbid obesity, the jejunooileal bypass, was first performed in 1954. However, this purely malabsorptive operation led to unacceptable morbidity and mortality related to bacterial overgrowth and liver damage [27]. Focus shifted away from purely malabsorptive procedures until the 1970s when biliopancreatic diversion (BPD) was first described [28], with eventual description of duodenal switch (DS) in 1993 [29]. This operation has been applied laparoscopically with effective weight loss [30].

Gastric bypass was introduced by Mason in 1966 as a combined restrictive–malabsorptive procedure [31]. Several variations and modifications of the original procedure have evolved over time, such as complete gastric transection, reduction in gastric pouch size, and application of a Roux-en-Y [32]. As of 2003, Roux-en-Y gastric bypass (RGB) accounted for over 80% of all bariatric procedures done in the USA [26]. Laparoscopic RGB was popularized and validated in the early 1990s by Wittgrove and Clark [33], and several corroborating series have followed [34–37]. Differences exist in the technique for laparoscopic gastrojejunostomy as part of the procedure, including transoral circular stapler [33], transgastric circular stapler [35], linear stapler [36], and handsewn [37], but all are supported in the literature as producing similar safety and weight loss results.

Mason and Printen developed a purely restrictive operation, the gastroplasty, in the early 1970s [38]. This operation later developed into vertical banded gastroplasty (VBG) [39], and ultimately laparoscopic VBG by the 1990s [40]. Despite efforts to simplify the procedure [41], gastroplasty operations decreased and only accounted for 7% of US bariatric procedures in 2002 [26]. Stomach
banding for weight loss, originally introduced in the 1980s with non-adjustable devices, became popular in the early 1990s [42]. In 1993, Belachew and Legrand placed the first laparoscopic adjustable gastric band (AGB) using the LAP-BAND® system (Allergan Inc, Irvine, CA, USA) [43]. Although there are multiple versions of AGB available for laparoscopic use, most published results derived from the LAP-BAND® system. Laparoscopic adjustable bands quickly became popular worldwide because of the relative ease of placement and safety. The LAP-BAND® system was not approved for use in the USA until 2001, and utilization has increased steadily. A recent worldwide survey revealed the laparoscopic AGB accounted for 24% of obesity operations, while 26% were laparoscopic RGB and 23% were open gastric bypass [44].

Another contemporary restrictive procedure that derives from the concept of vertical gastroplasty is the laparoscopic sleeve gastrectomy (LSG). LSG developed as a first-stage procedure before duodenal switch or gastric bypass in high-risk patients [45, 46]. Studies have shown that LSG used in this manner reduces weight, comorbidities, and operative risk (ASA score) at the time of a second bariatric procedure [47–49]. There is increasing application of LSG as a primary weight loss operation [45, 46, 50, 51]. Evolving data demonstrate LSG provides substantial weight loss and resolution of comorbidities to 3–5 years follow-up [45, 47, 52–54]. Early comparative data demonstrate percent EBWL at 1 year superior to AGB and approaching that of RGB and BPD [55]. There are other minimally invasive weight loss procedures in developmental stages. Gastric pacing, which has been in development in Europe for over 10 years, has shown acceptable safety and early efficacy (<15 months), though its use is appropriately limited to clinical trials until more mature data become available [56].

Guidelines for selecting validated bariatric procedures

- Laparoscopic RGB, gastric banding by VBG or AGB, and BPD±DS are established and validated bariatric procedures that may be performed laparoscopically (level II, grade A).
- LSG is validated as providing effective weight loss and resolution of comorbidities to 3–5 years (level II, grade C).

Patient selection considerations

According to the 1991 National Institutes of Health (NIH) consensus conference on gastrointestinal surgery for severe obesity, patients are candidates if they are morbidly obese (BMI > 40 kg/m² or ≥ 35 kg/m² with comorbidities), have failed attempts at diet and exercise, are motivated and well informed, and are free of significant psychological disease [57]. In addition, the expected benefits of operation must outweigh the risks. Surgery for morbid obesity has a low failure rate, with a mean EBWL of 61.2% [22]. Adverse events vary between procedures, but may reach 20% in high risk patients. Mortality rates approximate 0.1% for gastric banding, 0.5% for RGB, and 1.1% for BPD [22]. There are no absolute contraindications to bariatric surgery. Relative contraindications to surgery may include severe heart failure, unstable coronary artery disease, end-stage lung disease, active cancer diagnosis/treatment, cirrhosis with portal hypertension, uncontrolled drug or alcohol dependency, and severely impaired intellectual capacity. Crohn’s disease may be a relative contraindication to RGB [58] and BPD [59], and is listed by the manufacturer as a contraindication to the LAP-BAND® system. Laparoscopic surgery may be difficult or impossible in patients with giant ventral hernias, severe intra-abdominal adhesions, large liver, high BMI with central obesity or physiological intolerance of pneumoperitoneum. Surgeons performing bariatric surgery should possess the necessary skills to perform open bariatric surgery in the event it becomes necessary to convert to an open procedure [32].

Weight loss surgery for individuals with BMI ≤ 30–35 kg/m² and comorbidities merits consideration given the poor results of nonoperative weight loss regimens [60]. One controlled trial of laparoscopic AGB in this group found superior weight loss, resolution of metabolic syndrome and improvement in quality of life versus medical management at 2-year follow-up [61]. Another report of 37 patients undergoing RGB showed excellent weight loss and near-complete resolution of comorbidities [62]. Further data are necessary before surgery for BMI < 35 kg/m² becomes standard practice.

Early in the laparoscopic bariatric era, many traditional programs declined super-obese (BMI > 50 kg/m²) or supersuper-obese patients (BMI > 60 kg/m²) because of perceived high risk and technical challenge. However, as endosurgical techniques and equipment have improved, laparoscopic RGB and AGB have been more liberally applied at extreme BMIs, with consequent health and quality-of-life benefits, acceptable rates of morbidity and mortality, but lower EBWL [63–71]. Laparoscopic BPD+DS may also be appropriate for super-obese patients given the superior weight loss over laparoscopic RGB [72].
Age restrictions are less rigidly employed in the current era of refined anesthesiology, effective critical care, and high quality surgical outcomes. Laparoscopic bariatric surgery has been performed in patients older than 55–60 years [73–75], but with comparatively less weight loss, longer length of stay, higher morbidity and mortality, and less complete resolution of comorbidities compared with younger patients. Still, the reduction in comorbidities supports use of laparoscopic RGB or laparoscopic AGB in well-selected older patients [76–83]. At the time of the NIH consensus conference in 1991, bariatric surgery for morbidly obese children and adolescents was not advised because of insufficient data. However, with pediatric obesity increasing in prevalence and severity, interest in adolescent bariatric surgery is growing [84]. RGB is well tolerated and produces excellent weight loss in patients younger than 18 years with 10-year follow-up [85–91]. Advocates believe weight reduction at an early age will prevent or minimize emotional and physical consequences of obesity [92]. Well-designed prospective studies are just emerging to better define the place for adolescent bariatric surgery [93].

**Guidelines for patient selection**

- 1991 NIH consensus guidelines provide valid but incomplete patient selection criteria for contemporary bariatric procedures including laparoscopic BPD ± DS, RGB, VGB and AGB (level II, grade A).
- Other well-selected patients may benefit from laparoscopic bariatric surgery by experienced surgeons:
  - BMI > 60 kg/m² (level II, grade A).
  - Patients > 60 years (level II, grade B).
- Adolescent bariatric surgery (age < 18 years) has been proven effective but should be performed in a specialty center (level II, grade B). Patient selection criteria should be the same as used for adult bariatric surgery (level II, grade C).
- Individuals with BMI 30–35 kg/m² may benefit from laparoscopic bariatric surgery (level I, grade B).

**Bariatric program and facility**

The etiology of morbid obesity seems to involve genetic, environmental, metabolic, and psychosocial factors [94]. Therefore, treatment of the bariatric patient lends itself to a team approach for systematic evaluation and management [95]. Although a multidisciplinary team is seen as an important component of a bariatric surgery practice [32, 56, 96, 97], no comparative clinical trials have proven this. The team leader is the surgeon, who is complimented by nurses, physician extenders and clerical staff for scheduling, insurance precertification, and coordination of patient flow. The surgeon must have acquired the proper education and hands-on training as per the SAGES Guidelines for Institutions Granting Bariatric Privileges Using Laparoscopic Techniques. Other important team members include nutritionists, psychologists with specific training and experience, and medical subspecialists (endocrinologists, anesthesiologists, radiologists, pulmonologists, gastroenterologists, etc.) to help evaluate and optimize patients preoperatively and to provide care postoperatively if necessary [32, 96, 97]. The institutional needs of a bariatric program extend across outpatient and inpatient environments. It is important to have office and hospital furniture, equipment, clothing, fixtures, beds, and wheelchairs that are appropriate and comfortable for patients with morbid and supermorbid obesity. In the operating room, specially rated tables and attachments, extra-long instruments, and appropriate staplers and retractors are necessary [97]. Healthcare providers and staff must be experienced with and sensitive to the special needs of bariatric patients, and protected against ergonomic and lifting injuries.

Postoperative support groups are also an important aspect of a bariatric program and may improve postoperative results and limit relapse [32, 97, 98, 99]. Two nonrandomized studies have shown that patients attending support groups achieve greater weight loss than those who do not [100, 101]. Hospital annual case volume above 100 may be associated with reduced morbidity and mortality and improved costs [102]. Higher surgeon volume has been associated with reduced mortality [103]. Center of Excellence designation programs have gained traction [95] and are maintained by the American College of Surgeons [104] and the American Society for Metabolic and Bariatric Surgery [105].

**Guidelines for bariatric programs**

- Bariatric surgery programs should include multidisciplinary providers with appropriate training and experience (level III, grade C).
• Institutions must accommodate the special needs of bariatric patients and their providers (level III, grade C).
• Participation in support groups may improve outcomes after bariatric surgery (level II, grade B).

Preoperative workup
The preoperative evaluation is similar for all bariatric procedures. The components include determining a patient’s indications for surgery, identifying issues which may interfere with the success of the surgery, and assessing and treating comorbid diseases. Typical assessment includes psychological testing, nutrition evaluation, and medical assessment [97, 106].

Psychological evaluation
Patients referred for bariatric surgery are more likely than the overall population to have psychopathology such as somatization, social phobia, obsessive–compulsive disorder, substance abuse/dependency, binge-eating disorder, post-traumatic stress disorder, generalized anxiety disorder, and depression [107]. Patients with psychiatric disorders may have a suboptimal outcome after bariatric surgery [107]. However, no consensus recommendations exist regarding preoperative psychological evaluation [106, 108]. A recent survey reported that 88% of US bariatric programs utilize some psychological evaluation, with half requiring a formal standardized assessment [106]. Many insurance companies require such psychological evaluation prior to granting precertification for a bariatric procedure. Nevertheless, the bulk of evidence shows no relationship between preexisting axis I psychiatric diagnosis or axis II personality disorder and total weight loss [106, 109, 110]. It is not certain which psychosocial factors predict success following bariatric surgery [108], yet many programs exclude patients who are illicit drug abusers, have active uncontrolled schizophrenia or psychosis, severe mental retardation, heavy alcohol use, or lack of knowledge about the surgery [106].

Nutrition consult
The nutrition professional is an integral part of multidisciplinary bariatric care [111, 112]. He or she is charged with nutritional assessment, diet education regarding postoperative eating behaviors, and preoperative weight loss efforts [113]. Preoperative very-low-calorie diet for 6 weeks has been shown to reduce liver volume by 20% and to improve access to the upper stomach during laparoscopic surgery [114, 115], with 80% of the volume change occurring in the first 2 weeks [114]. Furthermore, patients who are able to achieve 10% EBWL preoperatively have shorter hospitalization and more rapid weight loss [116].

Despite the wide utilization of preoperative nutritional efforts, and the requirement by many insurance companies for dietary counseling, data are still needed to prove association with postoperative weight loss or dietary compliance [117, 118]. No evidence-based, standardized dietary guidelines exist for either pre- or postoperative nutritional management of the bariatric patient, and no convincing data support the need for routine use of nutrition specialists after operation. Outcome studies and clinical trials are necessary to help define the role of the nutrition professional in the bariatric team.

Preoperative medical evaluation
Medical assessment prior to bariatric surgery is similar to abdominal operations of the same magnitude. Thorough history and physical examination with systematic review is used to identify comorbidities that may complicate the surgery. Consultation with a medical subspecialist is often necessary to optimize medical conditions to reduce perioperative risk.

Routine laboratory evaluation typically includes complete blood count, metabolic profile, coagulation profile, lipid profile, thyroid function tests, and ferritin. Vitamin B12, and fat-soluble vitamin levels may be evaluated if considering a malabsorptive procedure. Cardiovascular evaluation includes electrocardiogram and possible stress test to identify occult coronary artery disease. Respiratory evaluation may include chest X-ray, arterial blood gas, and pulmonary function tests. Sleep apnea may be diagnosed by sleep study and the patient started on continuous positive airway pressure prior to surgery. Upper endoscopy may be used if suspicion of gastric pathology exists. If H. pylori infection is present, preoperative therapy is advised [119]. The liver may be assessed by hepatic profile and ultrasound. In cases of suspected cirrhosis, biopsy may be indicated. Ultrasound may be used to detect gallstones, allowing the surgeon to decide on concomitant cholecystectomy [98, 120].

Guidelines for preoperative preparation
• A psychological evaluation is commonly part of the preoperative work-up of bariatric patients (level III, grade C).
• Treated psychopathology does not preclude the benefits of bariatric surgery (level II, grade B).
• Preoperative weight loss may be useful to reduce liver volume and improve access for laparoscopic bariatric procedures (level II, grade B), but mandated preoperative weight loss does not affect postoperative weight loss or comorbidity improvements (level I, grade B).

### Surgical techniques and outcomes (presented in order of introduction above)

#### Laparoscopic biliopancreatic diversion

**Introduction**

After jejunoileal bypass was abandoned [121], most of the bariatric community focused on restrictive operations [122]. However, Scopinaro revisited the value of malabsorption in his description of the BPD in the late 1970s [28]. Since then, modifications have included the duodenal switch [123], the sleeve gastrectomy [29], and the laparoscopic approach [124]. DS diminishes the most severe complications of BPD, including dumping syndrome and peptic ulceration of the anastomosis [125]. Sleeve gastrectomy spares the lesser curvature, vagus nerves and pylorus, in contrast to the original distal gastrectomy, though theoretical beneficial effects on eating behavior, weight loss and side-effects are not universally reported [125, 126]. The laparoscopic approach decreases wound complications, pain and hospital length of stay [127].

**Technical considerations**

Standard technique for BPD+DS involves dividing the small bowel 250 cm above the ileocecal valve with a stapler, and then forming a biliopancreatic limb by connecting the bowel proximal to the transection to a point 100 cm above the ileocecal valve. The bowel distal to the transection is elevated as an alimentary limb to the upper abdomen. Sleeve resection creates a tubularized stomach of approximately 100 cm³. The duodenum is divided 3 cm distal to the pylorus, and duodenileostomy establishes continuity of the alimentary limb. Limb lengths determine weight loss and complications. A common limb that is too long will provide inadequate weight loss, whereas one too short will cause debilitating diarrhea and nutritional deficiencies. Gastric remnant size should provide some restriction but not prevent initiation of protein digestion.

Whether BPD should be tailored to patient characteristics such as age, size or BMI is uncertain [128]. Scopinaro, in his original animal study [129], found “insertion of the bypass into the ileum at a distance from the ileocecal valve equivalent to one-sixth of the intestinal length allows adequate weight loss with minimal complications.” However, by the time of his human studies [28], he noted that “the exact length of the common ileal segment and the length of the jejunum in the biliopancreatic tract required to achieve maximum weight reduction with minimum complications have yet to be determined.” Hess [130] reports excellent results by measuring small bowel length and then distributing 10% to the common channel and 40% to the alimentary limb. A large Spanish series reports excellent outcomes with a common channel of 60 cm and an alimentary limb of 200–360 cm [131, 132]. A US study suggests common channels longer than 100 cm result in inferior results [132]. In a comparative study of outcomes and complications, 100 cm common channel was superior to 50 cm, and sleeve gastrectomy was superior to distal gastrectomy [125]. Though there is a paucity of comparative data between open and laparoscopic BPD, a few comments can be made on the utility of the minimally invasive procedure. Firstly, because the details of the resection and reconstruction are the same, long-term outcomes are likely to be similar. Indeed, at 1 and 3 years follow-up, weight loss is similar to that achieved by open surgery [133, 134]. Laparoscopic BPD has reduced hospital stay and complications, mainly due to a lower rate of wound infections and dehiscence [127]. Laparoscopic BPD is an advanced, complex and feasible technique in bariatric surgery, and one which has a steep learning curve [135].

**Outcomes**

BPD ± DS initiates dramatic weight loss during the first 12 postoperative months, which continues at a slower rate over the next 6 months. Weight loss is durable up to at least 5 years postoperatively. Ninety-five percent of patients with BMI>50 kg/m², and 70% of those with BMI>50 kg/ m², achieve greater than 50% excess body weight loss [29, 136, 137]. Weight may be regained over time [138], highlighting the importance of long-term follow-up. BPD dramatically impacts comorbidities. At least 90% of patients with type 2 diabetes will cease diabetic medications by 12–36 months [127, 128, 139]. Of hypertensive patients 50–80% will be cured, with another 10% experiencing improvement [140–142]. Up to 98% of patients with obstructive sleep apnea symptoms will have resolution [143, 144]. Although BPD, RGB, and AGB are all superior to nonsurgical therapy, the relative effectiveness of these procedures has not been fully compared. Data available are rarely randomized or controlled, and often compare non-equivalent cohorts. Nonetheless, available data suggest the weight loss effect of BPD is greater and more durable than laparoscopic AGB [143, 145]. Likewise, BPD may be superior to RGB in patients with BMI ≥50 kg/m² [71].
A meta-analysis examining studies published between 1990 and 2003 found BPD resulted in more weight loss and improvement of diabetes, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obstructive sleep apnea than any other type of bariatric procedure [22]. Despite the favorable reports of the biliopancreatic diversion and duodenal switch procedure for the treatment of morbid obesity, it has been slow to gain widespread acceptance [29].

**Postoperative**

An upper gastrointestinal series is typically performed in the early postoperative period to exclude contrast extravasation. If normal, a clear liquid diet is commenced, with gradual introduction of solids. Discharge is usually within 4–5 days. Close follow-up is recommended in the postoperative period. For example, visits at 2 and 6 weeks, then quarterly for the first year, biannually for the second year, and annually thereafter would be one acceptable strategy [126, 131]. Assessments are made by both the surgeon and nutritionist, and biochemical surveillance by complete blood count, chemical metabolic profile, and parathormone level is performed at intervals. An exercise program is helpful, as are multivitamin, iron, vitamin D, and calcium supplements.

**Complications**

The 30-day mortality of early laparoscopic BPD series ranges from 2.6 to 7.6% [134, 147]. Major complications, which occur in up to 25% of cases, may include early occurrence of anastomotic leak, duodenal stump leak, intra-abdominal infection, hemorrhage, and venous thromboembolism [29, 147–150], or later bowel obstruction, incarceration or stricture [151]. The performance of a sleeve gastrectomy as part of the BPD+DS allows patients two-thirds of their preoperative dietary volume without specific food intolerances. Between 70 and 98% maintain normal serum albumin 3 years after surgery [29, 126]. Diarrhea is a frequent chronic complication of BPD. Common channel length of 50 cm is associated with reports of diarrhea in most patients [126], whereas length of 100 cm is not [29]. Iron deficiency is common, with serious iron deficiency anemia (hemoglobin <10 mg/dl) occurring in 6% of patients [152]. Surveillance of biochemical and hematological markers of iron deficiency should drive replacement. Calcium and vitamin D malabsorption are also common, manifesting as secondary hyperparathyroidism [153]. Supplements do not prevent development of secondary hyperparathyroidism. Increase in bone resorption is known to occur irrespective of parathormone levels, suggesting a phenomenon of bone reshaping parallel to the loss of weight [154]. Due to fat malabsorption resulting from BPD, supplementation of fat-soluble vitamins is recommended. Deficiency of these vitamins is more likely with a shorter common channel. Cholelithiasis postoperatively occurs in 6% [155] to 25% [28]. Some surgeons advocate for routine cholecystectomy given the alteration in endoscopic accessibility to the biliary tract, whereas others argue for delayed cholecystectomy only if symptoms develop, since cholecystitis occurs uncommonly after BPD [156].

**Guidelines for laparoscopic BPD ± DS**
- In BPD, the common channel should be 60–100 cm, and the alimentary limb 200–360 cm (level II, grade C).
- DS diminishes the most severe complications of BPD, including dumping syndrome and peptic ulceration of the anastomosis (level II, grade C).
- BPD is effective in all BMI>35 kg/m² subgroups, with durable weight loss and control of co-morbidities beyond 5 years (level II, grade A).
- Laparoscopic BPD provides equivalent weight loss, shorter hospital stay, and fewer complications than open BPD (level III, grade C).
- BPD may result in greater weight loss (level II, grade A) and resolution of comorbidities (level II, grade B) than other bariatric surgeries, but with the highest mortality rate (level II, grade A).
- After BPD ± DS, close nutritional surveillance and supplementation are needed (level III, grade C).

### Laparoscopic Roux-en-Y gastric bypass

**Introduction**

Gastric bypass was first developed in the 1960s as a means to combine restrictive, malabsorptive, and behavioral components to achieve weight loss. Physiologic changes in the gastrointestinal tract after gastric bypass (dumping, neuroendocrine responses, etc.) also appear to influence weight loss and comorbidity improvements which may precede weight loss. Since then, modifications have included use of a small lesser curvature-based gastric pouch, gastric transection, Roux-en-Y reconstruction, and variations in length of the alimentary limb [157, 158]. Feasibility of the laparoscopic approach to RGB was first shown in the early 1990s [33].

**Technical considerations**

The stomach is divided to form a small proximal gastric pouch and the small intestine is reconstructed using a Roux-en-Y to form an alimentary limb. Although accurate measurement of pouch volume is difficult and prospective data are lacking, a retrospective study has suggested that smaller pouches may be associated with greater weight loss [159]. Most surgeons choose the transection point by measuring from the esophagogastric junction or by counting vascular arcades. When creating the Roux en-Y bypass, the jejunum is typically divided below the ligament of Treitz, and the distal segment is elevated and surgically connected to the gastric pouch to create the alimentary (Roux) limb, with variations on the path and method for anastomosis. The proximal bowel segment, also called the biliopancreatic limb, is usually connected to the alimentary limb 75–150 cm distal to the gastrojejunostomy. This reconstruction serves to bypass the distal stomach, duodenum and a portion of jejunum to create malabsorption [157].

Several authors have addressed the issue of limb length during RGB. In BMI ≤ 50 kg/m² patients, both retrospective [160] and prospective [161, 162] data fail to show a benefit for alimentary limbs longer than 150 cm. However, BMI >50 kg/m² patients who were randomized to a 250 cm rather than a 150 cm alimentary limb did show improved weight loss at 18 months, though the study was not powered to confirm this benefit at longer follow-up [162]. Other studies have examined the use of alimentary limbs longer than 300 cm for BMI > 50 kg/m² patients, and have found improved weight loss over standard RGB, but with increased nutritional deficiencies and need for reoperation [163, 164].

Laparoscopic RGB is a technically demanding procedure; the available literature suggests an experience of 50–150 cases is required for surgeons to become safe and proficient [34, 36, 165–168].

**Outcomes**

The literature comparing laparoscopic RGB to open RGB and to contemporary medical and surgical treatments for obesity includes several prospective randomized controlled trials [161, 169–175], a large prospective case-controlled cohort study [19], numerous case series, and four metaanalyses [2, 21, 22, 176].

Surgical therapy is clearly more effective than medical therapy in terms of weight loss and resolution of comorbidities. Morbidly obese patients employing behavioral and medical therapies alone actually gain weight in the long term [2, 19]. Surgical patients have lower 5 year mortality versus nonsurgical patients (0.68% versus 6.17%), despite 0.4% perioperative mortality [177].

Patients who undergo laparoscopic RGB typically experience 60–70% EBWL, with >75% control of comorbidities [2, 19, 21, 22]. In general, these outcomes are better than banding procedures, which have 45–50% EBWL and less predictable improvement of comorbidities, but are less than BPD ± DS which has 70–80% EBWL with excellent control of comorbidities [22].

<table>
<thead>
<tr>
<th>Operation</th>
<th>Diabetes resolved</th>
<th>Hypercholesterolemia improved</th>
<th>Hypertension resolved</th>
<th>Sleep apnea resolved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laparoscopic RGB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Open RGB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Open and laparoscopic RGB have similar efficacy. In prospective randomized trials [169–171, 174], there are no significant differences in weight loss up to 3 years follow-up. Similar results have been reported in cases series [176].

Postoperative
Close, long-term follow-up is recommended for patients after bariatric surgery [57]. A typical example for recommendations of follow-up after laparoscopic RGB would be at 1–3 weeks, followed by quarterly visits during the first year and annually thereafter, to assess weight loss, resolution of comorbidities, long-term complications, and need for continuing education and support. Patients are counseled to eat small, frequent meals of high protein and low carbohydrate content. They should take long-term vitamin supplements (multivitamins, Vitamin B12, and calcium with some patients requiring iron supplementation) and undergo periodic blood testing to identify and treat deficiencies early. Patients should be encouraged to develop regular exercise practices. Two retrospective studies on the impact of follow-up on outcomes after laparoscopic RGB have been done; one suggests patient follow-up does not play an important role while the other reports improved weight loss in patients compliant with follow-up at 1 year [178, 179].

Complications
The mortality rate after RGB ranges from 0.3% in case series to 1.0% in controlled trials, and the rate of preventable and nonpreventable adverse surgical events is 18.7% [21]. The mortality rate in a review of selected laparoscopic RGB series ranged from 0.5% to 1.1% [180]. Safety of laparoscopic RGB has been compared to open RGB, with laparoscopic patients having reduced incidence of iatrogenic splenectomy, wound infection, incisional hernia and perioperative mortality, but higher rates of bowel obstruction, intestinal hemorrhage, and stomal stenoses [181].

The most frequently reported perioperative complications associated with laparoscopic RGB are wound infection (2.98%), anastomotic leak (2.05%), gastrointestinal tract hemorrhage (1.93%), bowel obstruction (1.73%), and pulmonary embolus (0.41%), while the most frequently reported late complications are stomal stenosis (4.73%), bowel obstruction (3.15%), and incisional hernia (0.47%) [181].

Guidelines for laparoscopic RGB

- In laparoscopic RGB, a small lesser-curvature-based pouch that excludes the gastric fundus and a 75–150 cm alimentary (Roux) limb are effective for most patients (level II, grade B).
- Alimentary limbs longer than 150cm may improve intermediate-term weight loss but also may increase nutritional complications (level III, grade C).
- Laparoscopic RGB is similar in efficacy to open RGB (level I, grade A), with reduced early complications and risk of hernia (level II, grade B).
- Long-term follow-up is recommended and may improve weight-loss outcomes (level III, grade C).

Laparoscopic adjustable gastric banding

Introduction
In the 1980s, gastroplasty was the most common restrictive bariatric procedure, with the most commonly performed iteration being the vertical banded gastroplasty. However, due to poor long-term weight loss [182, 183] and a high rate of late complications, alternatives to this operation were sought [184].

Open gastric banding procedures inspired laparoscopic AGB, first described in 1993 [43], which involves the placement of a restrictive inflatable balloon device around the gastric cardia, approximately 1 cm below the gastroesophageal junction. This balloon is connected by tubing to a subcutaneous port which is attached to the rectus sheath. Saline injected into the port will cause balloon inflation which results in narrowing of the stomach at the level of the balloon. Various brands of laparoscopic AGB exist, though only the LAP-BAND® system and the REALIZE™ adjustable gastric band (Ethicon Endosurgery, Cincinnati, OH) currently have Food and Drug Administration (FDA) approval for use in the USA. The equivalence between the two FDA-approved devices in the USA has been demonstrated [185], but comparative trials with others devices do not yet exist.

Technical considerations
The laparoscopic AGB is best placed via a pars flaccida approach, that is, via a retrogastric tunnel between the pars flaccida medially and the angle of His laterally. This has equivalent efficacy to the
initially described perigastric approach, but has a significantly decreased rate of band slippage (i.e.,
gastric prolapse) [186–188]. The pars flaccida approach results in more extraneous tissue, particularly
the lesser curvature fat pad, being incorporated into the band. Compensation by placing a band of
greater diameter may be required to limit stomal obstruction.
At the time of placement, a peroral calibration balloon may be placed into the stomach, filled with 15–
25 cc of saline, allowing the band to be fastened below this level. A 15–25 cc pouch is thereby
created.
AGB avoids the risks of gastrointestinal stapling and anastomosis and allows complete reversibility.
Most authors agree laparoscopic AGB is less technically demanding and less morbid than laparoscopic
RGB [71, 189]. However, potential disadvantages of laparoscopic AGB compared to laparoscopic RGB
include the ongoing need for band adjustments, delayed or unsatisfactory weight loss [190], and
unique indications for reoperation such as pouch dilation, esophageal dilation, band slippage, band
erosion, port-site complications, or leaks from the device [185].

Outcomes
Laparoscopic AGB has been compared to intensive pharmacotherapy, behavioral modification, diet
modification, and exercise in patients with BMI 30–35 kg/m². In this population, laparoscopic AGB was
seen to be more effective in reducing weight, resolving metabolic derangements, and improving
quality of life [61].
Laparoscopic AGB is very effective at producing weight loss, with patients losing approximately 50%
of their excess body weight [22, 191]. This weight loss occurs in a gradual manner, with
approximately 35% EBWL by 6 months, 40% by 12 months, and 50% by 24 months. This percentage
appears to remain stable after 3–8 years based on the few studies providing this length of follow-up
[145, 192–194]. However, as many as 25% of laparoscopic AGB patients fail to lose 50% of their
excess body weight by 5 years [22, 190].
Laparoscopic AGB has positive effects on the comorbidities of obesity. Type 2 diabetes is improved in
about 90% of patients, due to increased insulin sensitivity and increased pancreatic beta-cell function
[195], and diabetic medications are eliminated in 64% [196, 197]. Following AGB, resolution of type 2
diabetes mirrors weight loss, and therefore is slower to occur than after RGB or BPD where the
diabetes is seen to begin to improve before significant weight loss [196, 198].
Symptoms of gastroesophageal reflux disease may be eliminated in at least 89% at 12 months, even
in patients with large hiatal hernias [199, 200], but with the side-effect of impaired lower esophageal
sphincter relaxation and possible altered esophageal motility [201]. Rate of obstructive sleep apnea
drops from 33% to 2% in laparoscopic AGB patients [202]. Major quality-of-life improvements are
seen after AGB placement, with all subscales of the SF–36 general quality-of-life questionnaire
significantly improved, particularly in areas of bodily pain, general health perception, and mental
health perception [203–20]